File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.3389/fimmu.2025.1534787
- Scopus: eid_2-s2.0-105000424326
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Article: Gut microbiota is associated with persistence of longer-term BNT162b2 vaccine immunogenicity
Title | Gut microbiota is associated with persistence of longer-term BNT162b2 vaccine immunogenicity |
---|---|
Authors | |
Keywords | BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine gut microbiota vaccine vaccine immunogenicity |
Issue Date | 27-Feb-2025 |
Publisher | Frontiers Media |
Citation | Frontiers in Immunology, 2025, v. 16 How to Cite? |
Abstract | Introduction: BNT162b2 immunogenicity wanes with time and we investigated association between gut microbiota and longer-term immunogenicity. Methods: This cohort study prospectively recruited adult BNT162b2 two-dose recipients from three vaccination centers in Hong Kong. Blood samples were collected at baseline and day 180 after first dose, and tested for neutralizing antibodies (NAb) against receptor-binding domain (RBD) of wild type SARS-CoV-2 virus using chemiluminescence immunoassay. Shotgun DNA metagenomic sequencing was performed to characterize baseline stool microbiome. Baseline metabolites were measured by gas and liquid chromatography-tandem mass spectrometry (GC-MS/MS and LC-MS/MS). Primary outcome was persistent high NAb response (defined as top 25% of NAb level) at day 180. Putative bacterial species and metabolic pathways were identified using linear discriminant analysis [LDA] effect size analysis. Multivariable logistic regression adjusting for clinical factors was used to derive adjusted odds ratio (aOR) of outcome with bacterial species and metabolites. Results: Of 242 subjects (median age: 50.2 years [IQR:42.5-55.6]; male:85 [35.1%]), 61 (25.2%) were high-responders while 33 (13.6%) were extreme-high responders (defined as NAb≥200AU/mL). None had COVID-19 at end of study. Ruminococcus bicirculans (log10LDA score=3.65), Parasutterella excrementihominis (score=2.82) and Streptococcus salivarius (score=2.31) were enriched in high-responders, while Bacteroides thetaiotaomicron was enriched in low-responders (score=-3.70). On multivariable analysis, bacterial species (R. bicirculans–aOR: 1.87, 95% CI: 1.02-3.51; P. excrementihominis–aOR: 2.2, 95% CI: 1.18-4.18; S. salivarius–aOR: 2.09, 95% CI: 1.13-3.94) but not clinical factors associated with high response. R. bicirculans positively correlated with most metabolic pathways enriched in high-responders, including superpathway of L-cysteine biosynthesis (score=2.25) and L-isoleucine biosynthesis I pathway (score=2.16) known to benefit immune system. Baseline serum butyrate (aOR:10.00, 95% CI:1.81-107.2) and isoleucine (aOR:1.17, 95% CI:1.04-1.35) significantly associated with extreme-high vaccine response. Conclusion: Certain gut bacterial species, metabolic pathways and metabolites associate with longer-term COVID-19 vaccine immunogenicity. |
Persistent Identifier | http://hdl.handle.net/10722/355314 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ng, Ho Yu | - |
dc.contributor.author | Liao, Yunshi | - |
dc.contributor.author | Cheung, Ching Lung | - |
dc.contributor.author | Zhang, Ruiqi | - |
dc.contributor.author | Chan, Kwok Hung | - |
dc.contributor.author | Seto, Wai-Kay | - |
dc.contributor.author | Leung, Wai K | - |
dc.contributor.author | Hung, Ivan F N | - |
dc.contributor.author | Lam, Tommy TY | - |
dc.contributor.author | Cheung, Ka Shing | - |
dc.date.accessioned | 2025-04-03T00:35:07Z | - |
dc.date.available | 2025-04-03T00:35:07Z | - |
dc.date.issued | 2025-02-27 | - |
dc.identifier.citation | Frontiers in Immunology, 2025, v. 16 | - |
dc.identifier.uri | http://hdl.handle.net/10722/355314 | - |
dc.description.abstract | <p><strong>Introduction:</strong> BNT162b2 immunogenicity wanes with time and we investigated association between gut microbiota and longer-term immunogenicity.</p><p><strong>Methods:</strong> This cohort study prospectively recruited adult BNT162b2 two-dose recipients from three vaccination centers in Hong Kong. Blood samples were collected at baseline and day 180 after first dose, and tested for neutralizing antibodies (NAb) against receptor-binding domain (RBD) of wild type SARS-CoV-2 virus using chemiluminescence immunoassay. Shotgun DNA metagenomic sequencing was performed to characterize baseline stool microbiome. Baseline metabolites were measured by gas and liquid chromatography-tandem mass spectrometry (GC-MS/MS and LC-MS/MS). Primary outcome was persistent high NAb response (defined as top 25% of NAb level) at day 180. Putative bacterial species and metabolic pathways were identified using linear discriminant analysis [LDA] effect size analysis. Multivariable logistic regression adjusting for clinical factors was used to derive adjusted odds ratio (aOR) of outcome with bacterial species and metabolites.</p><p><strong>Results:</strong> Of 242 subjects (median age: 50.2 years [IQR:42.5-55.6]; male:85 [35.1%]), 61 (25.2%) were high-responders while 33 (13.6%) were extreme-high responders (defined as NAb≥200AU/mL). None had COVID-19 at end of study. <em>Ruminococcus bicirculans</em> (log<sub>10</sub>LDA score=3.65), <em>Parasutterella excrementihominis</em> (score=2.82) and <em>Streptococcus salivarius</em> (score=2.31) were enriched in high-responders, while <em>Bacteroides thetaiotaomicron</em> was enriched in low-responders (score=-3.70). On multivariable analysis, bacterial species (<em>R. bicirculans</em>–aOR: 1.87, 95% CI: 1.02-3.51; <em>P. excrementihominis</em>–aOR: 2.2, 95% CI: 1.18-4.18; S. <em>salivarius</em>–aOR: 2.09, 95% CI: 1.13-3.94) but not clinical factors associated with high response. <em>R. bicirculans</em> positively correlated with most metabolic pathways enriched in high-responders, including superpathway of L-cysteine biosynthesis (score=2.25) and L-isoleucine biosynthesis I pathway (score=2.16) known to benefit immune system. Baseline serum butyrate (aOR:10.00, 95% CI:1.81-107.2) and isoleucine (aOR:1.17, 95% CI:1.04-1.35) significantly associated with extreme-high vaccine response.</p><p><strong>Conclusion:</strong> Certain gut bacterial species, metabolic pathways and metabolites associate with longer-term COVID-19 vaccine immunogenicity.</p> | - |
dc.language | eng | - |
dc.publisher | Frontiers Media | - |
dc.relation.ispartof | Frontiers in Immunology | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | BNT162b2 (Pfizer-BioNTech) | - |
dc.subject | COVID-19 vaccine | - |
dc.subject | gut microbiota | - |
dc.subject | vaccine | - |
dc.subject | vaccine immunogenicity | - |
dc.title | Gut microbiota is associated with persistence of longer-term BNT162b2 vaccine immunogenicity | - |
dc.type | Article | - |
dc.identifier.doi | 10.3389/fimmu.2025.1534787 | - |
dc.identifier.scopus | eid_2-s2.0-105000424326 | - |
dc.identifier.volume | 16 | - |
dc.identifier.eissn | 1664-3224 | - |
dc.identifier.issnl | 1664-3224 | - |